Clinical trials · Tennessee
Metastatic Cancer clinical trials in Tennessee
We’re tracking 193 recruiting metastatic cancer studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Nashville, TennesseeAges 18 years+ - NCT06568692RecruitingPhase 2
Study of PCS6422 with capecitabine for advanced breast cancer
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Nashville, TennesseeAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Knoxville, TennesseeAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Nashville, TennesseeAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Knoxville, TennesseeAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Collierville, TennesseeAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Nashville, TennesseeAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Nashville, TennesseeAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Nashville, TennesseeAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Nashville, TennesseeAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Nashville, TennesseeAges 18 years+ - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
Chattanooga, TennesseeAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Dickson, TennesseeAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Chattanooga, TennesseeAges 18 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Kingsport, TennesseeAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Nashville, TennesseeAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Germantown, TennesseeAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Nashville, TennesseeAges 18 years+ - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Knoxville, TennesseeAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT05024929Recruiting
Test targeted drugs to help radioactive iodine reach thyroid cancer
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
Memphis, TennesseeAges birth+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Chattanooga, TennesseeAges 18 years+
Metastatic Cancer trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting metastatic cancer studies listed above.
- SCRI Oncology Partners · 9 studies
- Sarah Cannon Research Institute · 7 studies
- Tennessee Oncology · 4 studies
- Baptist Memorial Hospital and Cancer Center-Collierville · 2 studies
- Baptist Memorial Hospital and Cancer Center-Memphis · 2 studies
- Local Institution · 2 studies
- Tennessee Oncology Chattanooga · 2 studies
- University of Tennessee Medical Center · 2 studies
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Cancer trials in other states
Common questions
- Are there metastatic cancer clinical trials in Tennessee?
- Yes. We're currently tracking 193 recruiting metastatic cancer studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.